Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Medtronic Posts Better-Than-Expected Earnings. Here’s Why the Stock Is Falling.

2026-02-17
Medical device maker Medtronic reported quarterly earnings and net sales that topped consensus views. Medtronic on Tuesday posted fiscal third-quarter adjusted earnings of $1.36 a share, narrowly beating analysts’ forecasts of $1.34. Medtronic’s profit declined from the same period last year on a non-adjusted basis, slipping to $1.14 billion from $1.29 billion.

DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook

2026-02-15
DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly revenue. This was well ahead of the $1.25 billion that Wall Street expected, and a 13% year over year growth. According to management, this […]

DexCom Expands G7 And Stelo To Deepen CGM Ecosystem Engagement

2026-02-13
DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of AI-enabled upgrades to its Stelo platform, aimed at providing deeper nutritional insights and personalized metabolic health guidance. These product moves expand DexCom's presence in diabetes and metabolic health management and introduce new data driven tools for everyday decision making. DexCom...

Top S&P500 movers in Friday's session

2026-02-13
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.

Friday's session: top gainers and losers in the S&P500 index

2026-02-13
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth

2026-02-13
DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.

Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations

2026-02-13
Dexcom's 2026 revenue estimates lagged analysts' expectations, according to data compiled by the London Stock Exchange Group (LSEG).

Why Is DexCom (DXCM) Stock Rocketing Higher Today

2026-02-13
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for both revenue and earnings.

Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday?

2026-02-13
After Thursday's broad-based tech selloff, Wall Street staged a rebound as a softer-than-expected inflation print reinforced expectations for interest-rate cuts during the year.

DexCom, Inc. Q4 2025 Earnings Call Summary

2026-02-13
Moby summary of DexCom, Inc.'s Q4 2025 earnings call